Bank of New York Mellon Corp Has $1.30 Million Position in Enfusion, Inc. (NYSE:ENFN)

Bank of New York Mellon Corp raised its position in shares of Enfusion, Inc. (NYSE:ENFN) by 3.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 126,541 shares of the company’s stock after purchasing an additional 4,032 shares during the quarter. Bank of New York Mellon Corp’s holdings in Enfusion were worth $1,303,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Paloma Partners Management Co acquired a new stake in Enfusion during the 3rd quarter valued at $157,000. Centiva Capital LP increased its stake in shares of Enfusion by 5.0% in the third quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock worth $243,000 after acquiring an additional 1,227 shares during the last quarter. Azora Capital LP increased its stake in shares of Enfusion by 6.8% in the third quarter. Azora Capital LP now owns 29,827 shares of the company’s stock worth $283,000 after acquiring an additional 1,890 shares during the last quarter. Quest Partners LLC acquired a new position in shares of Enfusion in the third quarter worth $308,000. Finally, Rhumbline Advisers increased its stake in shares of Enfusion by 3.0% in the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock worth $643,000 after acquiring an additional 1,796 shares during the last quarter. 81.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ENFN shares. Stifel Nicolaus upped their price target on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. William Blair reissued a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. Finally, Piper Sandler increased their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd.

Enfusion Stock Performance

Enfusion stock opened at $11.10 on Monday. The business’s 50-day simple moving average is $11.16 and its 200-day simple moving average is $10.11. The firm has a market capitalization of $1.43 billion, a PE ratio of 277.44, a PEG ratio of 1.85 and a beta of 0.95. Enfusion, Inc. has a 52 week low of $7.83 and a 52 week high of $11.80.

Enfusion (NYSE:ENFN) last released its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Enfusion had a return on equity of 6.67% and a net margin of 1.70%. The firm had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. Research analysts forecast that Enfusion, Inc. will post 0.06 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Bronwen Bastone sold 3,126 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total value of $35,573.88. Following the transaction, the insider now directly owns 221,875 shares of the company’s stock, valued at $2,524,937.50. The trade was a 1.39 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Bradley Herring sold 4,645 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total value of $52,860.10. Following the completion of the transaction, the chief financial officer now directly owns 324,689 shares in the company, valued at $3,694,960.82. The trade was a 1.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 77,346 shares of company stock valued at $868,109 over the last three months. 36.44% of the stock is owned by corporate insiders.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.